Letter to the editor regarding "Bone metastases from differentiated thyroid carcinoma: heterogenous tumor response to radioactive Iodine therapy and overall survival"

Affiliations

Comment

Maria José Veloza Vega et al. Eur J Nucl Med Mol Imaging. 2022 Sep.

. 2022 Sep;49(11):3622-3623.

doi: 10.1007/s00259-022-05869-8. Epub 2022 Jun 15.

No abstract available

Comment on

Bone metastases from differentiated thyroid carcinoma: heterogenous tumor response to radioactive Iodine therapy and overall survival.
Jannin A, Lamartina L, Moutarde C, Djennaoui M, Lion G, Chevalier B, Vantyghem MC, Deschamps F, Hadoux J, Baudin E, Schlumberger M, Leboulleux S, Do Cao C. Jannin A, et al. Eur J Nucl Med Mol Imaging. 2022 Jun;49(7):2401-2413. doi: 10.1007/s00259-022-05697-w. Epub 2022 Feb 12. Eur J Nucl Med Mol Imaging. 2022. PMID: 35149914 Free PMC article.

1. Jannin A, Lamartina L, Moutarde C, Djennaoui M, Lion G, Chevalier B, Vantyghem MC, Deschamps F, Hadoux J, Baudin E, Schlumberger M, Leboulleux S, Do Cao C. Bone metastases from differentiated thyroid carcinoma: heterogenous tumor response to radioactive Iodine therapy and overall survival. Eur J Nucl Med Mol Imaging. 2022;49(7):2401–13. https://doi.org/10.1007/s00259-022-05697-w .
1. World Health Organization International Agency for Research on Cancer (IARC). GLOBOCAN 2020: Colombia fact sheets. [homepage on the internet]; 2020 [cited 2022 March 28]. Available from: https://gco.iarc.fr/today/data/factsheets/populations/170-colombia-fact-... .
1. Chung J-K, Cheon GJ. Radioiodine therapy in differentiated thyroid cancer: the first targeted therapy in oncology. Endocrinol Metab. 2014;29:233. https://doi.org/10.3803/enm.2014.29.3.233 . - DOI